Conference Call Information. Infinity will host a conference call today, Wednesday, July 18, 2012, at 8:30 a.m. ET to discuss the agreement and provide an update on it PI3K program. A live webcast of the conference call can be accessed in the “investors/media” section of Infinity’s website at xxx.xxxx.xxx. To participate in the conference call, please dial 0-000-000-0000 (domestic) or 0-000-000-0000 (international) five minutes prior to start time. An archived version of the webcast will be available on Infinity’s website for 30 days. About Infinity Pharmaceuticals, Inc. Infinity is an innovative drug discovery and development company seeking to discover, develop and deliver to patients best-in-class medicines for diseases with significant unmet need. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of the heat shock protein 90, phosphoinositide-3-kinase and fatty acid amide hydrolase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company’s website at xxx.xxxx.xxx.
Conference Call Information. Blueprint Medicines will host a conference call and live audio webcast for investors at 8:00 A.M. ET today. To participate in the conference call, please dial 000-000-0000 (domestic) or 000-000-0000 (international) and refer to conference ID 63223687. A live webcast of the conference call will be available by visiting the Investors section of Blueprint Medicines' website at xxxx://xx.xxxxxxxxxxxxxxxxxx.xxx. The archived webcast will be available on Blueprint Medicines' website approximately 2 hours after the call and will be available for 30 days following the call.
Conference Call Information. The Medicines Company and Alnylam will host a conference call today at 8:30 a.m. ET to discuss this new collaboration. To access the call, please dial 000-000-0000 (domestic) or 000-000-0000 (international) five minutes prior to the start time and refer to conference ID 96998933. A replay of the call will be available beginning at 11:30 a.m. ET. To access the replay, please dial 000-000-0000 (domestic) or 000-000-0000 (international) and refer to conference ID 96998933. A live audio webcast of the presentation will be available on The Medicines Company website at xxx.xxxxxxxxxxxxxxxxxxx.xxx, and on the News & Investors section of the Alnylam’s website, xxx.xxxxxxx.xxx About Hypercholesterolemia Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood which is known to increase the risk of coronary artery disease, the leading cause of death in the U.S. Some CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. forms of hypercholesterolemia can be treated through dietary restrictions, lifestyle modifications (e.g., exercise and smoking cessation) and medicines such as statins. However, a large proportion of patients with hypercholesterolemia are not achieving target LDL-C goals with statin therapy, including genetic familial hypercholesterolemia patients, acute coronary syndrome patients, high-risk patient populations (e.g., patients with coronary artery disease, diabetics, symptomatic carotid artery disease, etc.) and other patients that are statin intolerant. Severe forms of hypercholesterolemia are estimated to affect more than 500,000 patients worldwide, and as a result, there is a significant need for novel therapeutics to treat patients with hypercholesterolemia whose disease is inadequately managed by existing therapies. About ALN-PCS ALN-PCS is a systemically delivered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol). ALN-PCS therapies are PCSK9 synthesis inhibitors that lower levels of both intracellular and extracellular PCSK9, thereby phenocopying the human gen...
Conference Call Information. Management of Polestar and Xxxxx Guggenheim will host an investor conference call on Monday, September 27, 2021 at 9:00 am EDT / 3:00 pm CET to discuss the proposed business combination. The call can be accessed by dialing +1 (833) 470- 1428 (domestic toll-free number) or +0 (000) 000-0000 (international) and providing the conference ID 199774. A replay of the call can be accessed by dialing +0 (000) 000-0000 (domestic toll-free number) or +0 (000) 000-0000 (international) and providing the conference ID 643163#. Alternatively, a webcast of the call can be accessed by visiting xxxxx://xxx.xxxxxxxxxxx.xxx/ with the entry code “drive489”. A replay of the webcast can be accessed by visiting xxxxx://xxx.xxxxxxxxxxx.xxx/nrs/home/#!/?show=d413d154. About Polestar Polestar is a Swedish premium electric performance car brand founded by Volvo Cars and Geely Holding. Established in 2017, Polestar enjoys specific technological and engineering synergies with Volvo Cars and benefits from significant economies of scale as a result. The Company is headquartered in Gothenburg, Sweden, and its vehicles are available and on the road in fourteen active global markets across Europe, North America and China. In 2021, Polestar is expanding into five new markets in the Asia Pacific region. Polestar produces two electric performance cars. The Polestar 1 is a low-volume electric performance hybrid GT with a carbon fiber body, 609 hp, 1,000 Nm of torque and an electric-only range of 124 km (WLTP) – the longest of any hybrid car in the world. The Polestar 2 electric performance fastback is the Company’s first fully electric, high volume car. The Polestar 2 model range includes three variants with a combination of long- and standard range batteries as large as 78 kWh, and dual- and single-motor powertrains with as much as 300 kW / 408 hp and 660 Nm of torque. In the future, the Polestar 3 electric performance SUV is expected to join the portfolio, as well as the Precept – a design study vehicle released in 2020 that is slated for future production. Precept showcases the brand’s future vision in terms of sustainability, digital technology and design. In April 2021, Polestar announced an important goal of creating a truly climate-neutral car by 2030. About Gores Guggenheim, Inc. Gores Guggenheim, Inc. (Nasdaq: GGPI, GGPIW, and GGPIU) is a special purpose acquisition company sponsored by an affiliate of The Gores Group, LLC, founded by Xxxx Xxxxx, and by an affiliate of Guggenheim Capit...
Conference Call Information. Aegerion will host a conference call today at 8:00 am EST to discuss the Myalept acquisition. To listen to the conference call, dial (000) 000-0000 (international callers dial (000) 000-0000). In addition, the presentation will be webcast live, and may be accessed for up to 30 days following the call, by visiting the “Investors” section of Aegerion’s website, xxx.xxxxxxxx.xxx. An accompanying slide presentation also can be accessed via the “Investors” section of the Aegerion website. THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [*] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. NOTES TO EDITORS About Generalized Lipodystrophy Generalized lipodystrophy consists of a rare set of syndromes that are inherited or acquired through an autoimmune response and that are characterised by loss of fat tissue, typically from under the skin. The underlying reason is a deficiency in leptin, leading to an inability to store triglycerides in normal fat depots. This often leads to severe insulin resistance and diabetes, severe hypertriglyceridemia along with a concomitant increased risk of acute pancreatitis, and hepatic steatosis, which can lead to cirrhosis. Myalept™ (metreleptin for injection) INDICATION and IMPORTANT SAFETY INFORMATION for Myalept™ (metreleptin for injection) INDICATION Myalept™ (metreleptin for injection) is a recombinant human leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. LIMITATIONS OF USE • The safety and effectiveness of MYALEPT (metreleptin for injection) for the treatment of complications of partial lipodystrophy or for the treatment of liver disease, including nonalcoholic steatohepatitis (XXXX), have not been established. • MYALEPT is not indicated for use in patients with HIV-related lipodystrophy or in patients with metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent evidence of congenital or acquired generalized lipodystrophy. IMPORTANT SAFETY INFORMATION WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF LYMPHOMA • Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of end...
Conference Call Information. The Medicines Company and Alnylam will host a conference call today at 8:30 a.m. ET to discuss this new collaboration. To access the call, please dial 877-312-0000 (xxxxxxic) or 631-813-0000 (xxxxxxational) five minutes prior to the start time and refer to conference ID 96998933. A replay of the call will be available beginning at 11:30 a.m. ET. To access the replay, please dial 855-859-0000 (xxxxxxic) or 404-537-0000 (xxxxxxational) and refer to conference ID 96998933. A live audio webcast of the presentation will be available on The Medicines Company website at www.themxxxxxxxxxxxxxxx.xxx, xxx xx the News & Investors section of the Alnylam's website, www.alnyxxx.xxx Xxxxx Hypercholesterolemia Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood which is known to increase the risk of coronary artery disease, the leading cause of death in the U.S. Some forms of hypercholesterolemia can be treated through dietary restrictions, lifestyle modifications (e.g., exercise and smoking cessation) and medicines such as statins. However, a large proportion of patients with hypercholesterolemia are not achieving target LDL-C goals with statin therapy, including genetic familial hypercholesterolemia patients, acute coronary syndrome patients, high-risk patient populations (e.g., patients with coronary artery disease, diabetics, symptomatic carotid artery disease, etc.) and other patients that are statin intolerant. Severe forms of hypercholesterolemia are estimated to affect more than 500,000 patients worldwide, and as a result, there is a significant need for novel therapeutics to treat patients with hypercholesterolemia whose disease is inadequately managed by existing therapies. About ALN-PCS ALN-PCS is a systemically delivered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol). ALN-PCS therapies are PCSK9 synthesis inhibitors that lower levels of both intracellular and extracellular PCSK9, thereby phenocopying the human genetics observed in loss of function or null human PCSK9 mutations (N. Engl. J. Med. (2006) 354:1264-1272; Am. J. Hum. Genet. (2006) 79: 514-523). PCSK9 synthesis inhibition through an RNAi mechanism has the potential to lower tissue and circulating plasma PCSK9 protein levels resulting in higher LDL receptor levels in the liv...
Conference Call Information. Momenta will host a conference call for investors today at 10 am ET to discuss this important biosimilars collaboration with Mylan. The conference call will be webcast live and a link to the webcast may be accessed on the “Investors” section of the company’s website, xxx.xxxxxxxxxxxxx.xxx. Please go to the site at least 15 minutes prior to the call to register, Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 108 Confidential Treatment Requested by Momenta Pharmaceuticals, Inc. download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call. To access the call you may also dial (000) 000-0000 (domestic) or (000) 000-0000 (international) prior to the scheduled conference call time and provide the access code 21610391. A replay of the call will be available approximately two hours after the conclusion of the call. To access the replay, please dial (000) 000-0000 (domestic) or (000) 000-0000 (international) and provide the access code 21610391.
Conference Call Information. Management will host a conference call today, Wednesday, February 10, 2016 at 4:45 p.m. Eastern Time to discuss the transaction. Interested investors are invited to participate as follows: · Via Conference Call: Toll-Free: (000) 000-0000; International: (000) 000-0000 · Conference Call Replay: A recording will be available until February 17, 2016 at the following numbers: Toll-Free (000) 000-0000; International (000) 000-0000; Pass code 00000000 · Webcast: A live audio webcast will be accessible at xxx.xxxxxx-xxxxxx.xxx.
Conference Call Information. The companies will host a webcast call and presentation to discuss the proposed transaction as well as XXXX’x pipeline assets today, November 15, 2023, at 8:00 a.m. ET. The live webcast can be accessed here and on the Graphite Bio website at xxx.xxxxxxxxxxx.xxx in the Investors section or by calling 000-000-0000 or +0-000-000-0000. A replay of the webcast will be archived and available following the event. Advisors Xxxxxxx Partners is acting as exclusive financial advisor to Graphite Bio for the transaction and Xxxxxxx Procter LLP is serving as its legal counsel. BofA Securities is serving as lead financial advisor to XXXX for the merger. Xxxx is also serving as financial advisor to XXXX for the merger. BofA Securities is serving as lead placement agent on the PIPE financing. Xxxx, Xxxxx Xxxxxxx & Co. and Xxxxxxx Xxxxx & Company, L.L.C. are serving as co-placement agents for the PIPE financing. Xxxxxx & Xxxxxxx LLP is serving as legal counsel to the placement agents. Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx, P.C. is serving as legal counsel to XXXX. About XXXX Therapeutics XXXX Therapeutics is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical trials for the treatment of presbyopia. Presbyopia impacts an estimated 1.8 billion people globally and 128 million people in the United States. XXXX is headquartered in San Diego, California, and is backed by venture capital investors, including Versant Ventures, RA Capital Management, Alpha Wave Global, Point72, Samsara BioCapital, Sectoral Asset Management and RTW Investments. For more information, visit: XXXX-Xx.xxx. About Graphite Bio, Inc. Graphite Bio, Inc. has historically been a clinical-stage, next-generation gene editing company. In February 2023, Graphite Bio announced its decision to discontinue the development of nulabeglogene autogedtemcel (“nula-cel”), Graphite Bio’s lead product candidate for sickle cell disease, and to initiate a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from Graphite Bio’s product development assets and cash resources. For more information, please visit xxx.xxxxxxxxxxx.xxx. Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Pr...
Conference Call Information. Egalet’s management will host a conference call to discuss the commercial update: Date: Monday, January , 2015 Time: 8:00 a.m. EDT Webcast (live and archive): xxxx://xxxxxx.xxxxxxxxxxxx.xxx/eventsandwebcasts Dial-in numbers: 0-000-000-0000 (domestic) 0-000-000-0000 (international) Replay dial-in numbers: 0-000-000-0000 (domestic) 0-000-000-0000 (international) Conference Number: 10050459
